Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 16 of 16 for “"CYP3A5"”.
-
Regulation of CYP3A5 in Pancreatic Ductal Adenocarcinoma
<p>CYP3A5 is a drug metabolism enzyme that is polymorphically expressed in normal tissues and expressed in high amounts in some cancers, including pancreatic ductal adenocarcinoma (PDAC). There have been several published studies regarding CYP3A5 regulators, but there is still much to be discovered …
-
Vincristine Metabolism and the Role of CYP3A5
… P450 3A subfamily of enzymes possibly including CYP3A5, a genetically polymorphic enzyme. The contribution of CYP3A5 to the metabolism of vincristine was quantified by various in vitro models: cDNA-expressed enzymes, human liver microsomes, and human hepatocytes. With these models, the major CYP …
-
Selective Targeting of CYP3A5 Through Chemical and Genetic Approaches
… drug response. Within this family are CYP3A4 and CYP3A5, which collectively metabolize greater than half of all currently prescribed drugs. These promiscuous enzymes can bind a broad and structurally diverse array of compounds, in turn leading to an increased risk of their modulation via small …
-
Propoxyphene, Norpropoxyphene, and Proadifen (SKF-525A) Are Mechanism Based Inhibitors of CYP3A4, CYP3A5, and CYP3A in Human Liver Microsomes
… characterized in these studies with CYP3A4(+b5), CYP3A5(+b5) and pooled human liver microsomes. Time-dependent and concentration-dependent loss of activity of CYP3A was measured by formation of testosterone product. Propoxyphene and norpropoxyphene exhibited the greatest inhibition with CYP3A in …
-
THE IMPACT OF CYP3A4*22 AND CYP3A5*3 ON DEXAMETHASONE AND 6-HYDROXY-DEXAMETHASONE PHARMACOKINETICS IN PHASE 1/2 CANCER PATIENTS
CYP3A4 and CYP3A5 comprise the most abundantly expressed human CYP450 activity and participate in metabolism of an estimated 40% of all marketed drugs. However, their 10-100 fold inter-individual variability in activity may have a profound effect on outcomes from drug therapy. CYP3A4*22 and …
-
Associations of genetic variants in ABCB1, ABCG2, CYP3A4, CYP3A5, and SLCO1B1 with statin-associated muscle symptom (SAMS) in South African populations
… variability of ABCB1, ABCG2, CYP3A4, CYP3A5, and SLCO1B1, particularly in Asian and European populations. However, limited knowledge exists regarding the impact of pharmacogenetics on statin tolerance among South African patients. This study aimed to examine the relationships between …
-
Pharmacogenetics of resistant hypertension: evaluating the role of genetic variation in ABCB1, ADBR1, CES1, CYP3A4, CYP3A5, NEDD4L, NOS3, NR3C2 and SCNN1B among South African hypertensive patient
… nine genes, namely, ABCB1, ADBR1, CES1, CYP3A4, CYP3A5, NEDD4L, NOS3, NR3C2 and SCNN1B, in the development of resistant hypertension in South African patients. Knowledge of pharmacogenetic variants that play a role in resistant hypertension may potentially improve treatment and management of …
-
Pharmacokinetic-Pharmacogenetic-and-Pharmacodynamic Adherence Relationships in Cohort South African HIV Infected Children on Lopinavir-and Nevirapine-Based Regimens
… and genetic polymorphisms in the ABCB1, CYP3A4, CYP3A5 and SLCO1B1. CYP2B6 516G→T and CYP2B6 983T→C were associated with NVP CL/F. CYP2B6 983T→C was associated with NVP Cmin and AUC. Additionally, polymorphisms in the ABCB1 and CYP3A5 were independently associated with NVP CL/F, Cmin and AUC. …
-
Nuevos factores genéticos asociados a la predisposición de crisis en Porfiria Aguda Intermitente.
… los citocromos CYP2C9, CYP2C19, CYP2D6, CYP3A4 y CYP3A5 que actúen como factores de susceptibilidad para la manifestación de crisis agudas en los portadores de PAI. Material y métodos: Se realizó un estudio retrospectivo de la ocurrencia de crisis (PAI manifiesta) en 50 individuos portadores de …
-
Determination of Absolute Protein Content of Hepatic CYP4F Enzymes in Human Liver Microsomes Using LC/MS/MS Methodology and Comparison with Immunoquantification and Enzyme Activity
… LC/MS/MS for CYP4F2, CYP4F3B, CYP3A, CYP3A4, and CYP3A5. The contribution of CYP4F enzymes to the overall hepatic CYP "pie" was also determined. The observed enzyme protein values were then correlated with immunoquantified protein content and enzyme activity. The enzyme protein contents determined …
-
Bedeutung des Cytochrom-P450-2C9- und -3A5-Genpolymorphismus für Pharmakokinetik, Wirkungen und Nebenwirkungen von Delta-9-Tetrahydrocannabinol bei gesunden Probanden und Probandinnen
… Trägern des Genotyps CYP2C9*1/*1. Bezüglich des CYP3A5-Genpolymorphismus ließen sich keine signifikanten Unterschiede feststellen Schlussfolgerung: Die durch Polymorphismen des Enzyms CYP2C9 bedingten Unterschiede in der Pharmakokinetik von THC können in der forensischen Medizin hinsichtlich der …
-
Xenobiotic metabolism and zebrafish (danio rerio) larvae
… to mammalian cytochrome P450 (CYP) 1A1, CYP2B6, CYP3A5 and UDP-lucuronosyl-transferase (UGT) 1A1 were demonstrated to be expressed during normal embryonic development, with increased expression post hatching in Wik strain zebrafish larvae (72 hours post fertilisation, hpf). Activities towards …
-
Genetic Polymorphisms and the Treatment Outcome in Standard-Risk Pediatric Acute Lymphoblastic Leukemia
… were observed for the CYP1A1, CYP2B6, CYP3A4, CYP3A5, MTHFR C667T, MTHFR A1298G, or TYMS polymorphisms. The findings from this single institution study suggest that polymorphisms within genes of the GST superfamily may influence the treatment outcome in standard-risk ALL. They also point to the …
-
The pharmacologenetics of lopinavir in a cohort of black African HIV/AIDS patients
… the drug metabolising enzymes, CYP3A4 and CYP3A5; the hepatic uptake transporter, OATP1B1; and the efflux transporter, MRP2. Variation in the genes encoding these proteins may influence their functioning and hence LPV disposition. The aim of the study was to identify significant single …
-
Valor pronóstico y predictivo de polimorfismos en genes relacionados con el metabolismo y el mecanismo de acción del cabazitaxel en pacientes con cáncer de próstata avanzado
… y/o mecanismo de acción de cabazitaxel (CYP3A4, CYP3A5, ABCB1, TUBB1, CYP2C8). La presencia/ausencia de alelos mutados de los SNP seleccionados, se correlacionó con las características clínicas de CPRCm, la SLP, la SG y la toxicidad de cabazitaxel mediante la realización de análisis univariante y …
-
In vitro metabolism studies to inform physiologically-based pharmacokinetic modelling of mefloquine, ritonavir and proguanil
… the reported finding that polymorphisms of CYP3A5 do not affect mefloquine PK. Disease state may therefore have a bigger effect on the variability in mefloquine PK than variability in metabolism does. The model application for proguanil focussed on the potential effects of various CYP …